Contract Research Organization (CRO) / Biopharmaceutical Outsourcing Services
Strategic Profile
The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, and devices spanning Phase I to IV clinical development, while the Commercial Solutions segment provides commercialization, communications, and consulting services. The company is a leading integrated contract research and commercialization services provider, positioned as a strategic partner in the drug development lifecycle.
Cyborg Score Rationale
The stock has declined 44% over the past year and underperformed the S&P 500 by over 51% as of April 2026. Analyst consensus is Hold. The company is not in a good financial situation and faces a high risk of financial straits.
Top Insights
Stock has severely underperformed broader market, down 44% in 12 months (as of April 2026) versus S&P 500
TTM revenue of $5.41B (March 2026) reflects stable market position in clinical outsourcing and commercial solutions
Company faces significant operational challenges with analyst consensus at Hold and elevated financial risk metrics
(January 2026) Leadership appointment of Simon Bartle as Chief Human Resources Officer signals organizational changes
Named Competitors
Clinical Research Services — Integrated contract research and preclinical/clinical services
IQVIA Services — Clinical research, data analytics, and commercialization services
Parexel Services — Contract research and medical consulting services
Recent Developments
(January 2026) Appointed Simon Bartle as Chief Human Resources Officer
(2026) Strategic partnership expansion with causaLens and KAI Conversations for AI-driven biopharma services
Open the full interactive Syneos Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.